Business Wire

REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 2021

15.11.2021 17:01:00 EET | Business Wire | Press release

Share

Today, the Board of Directors of Reply [MTA, STAR: REY] approved the results as at 30 September 2021.

The Group's consolidated turnover in the first nine months of the year reached €1,073.4 million, an increase of 18.2% compared to €908.3 million recorded on 30 September 2020.

All indicators are positive for the period. Consolidated EBITDA was €183.2 million, an increase of 29.8% compared to the €141.1 million recorded in September 2020.

EBIT, from January to September, was €147.5 million, which is an increase of 29.0% compared to €114.4 million at September 2020.

Pre-tax profit, from January to September 2021, was €150.0 million (+31.9% compared to €113.8 million in 2020).

For the third quarter of the year, the Group’s performance is equally positive, with consolidated turnover for the period of €360.6 million, an increase of 23.0% compared to 2020.

EBITDA, from July to September 2021, was equal to €63.7 million, with an EBIT of €51.5 million and pre-tax profit of €51.3 million.

As at 30 September 2021, the Group’s net financial position was positive at €244.4 million. The net financial position as at 30 June 2021 was positive for €165.4 million.

“The first nine months of 2021 have been very positive in terms of both revenue and margins”, explains Mario Rizzante, Chairman of Reply. “In the last quarter, we additionally increased our investments in technology by companies in two principal fields of innovation: cloud and artificial intelligence.”

Mario Rizzante continues: “Our position in these areas means that Reply is increasingly involved in transforming entire sectors and supply chains. In the automotive sector, for example, we are engaged in projects related to self-driving vehicles and the definition of new electric grids; in the banking and insurance sector, we are working with the main players on redefining solutions to support the digitalization and automation of the main processes on cloud architectures; while in the telco sector, we are developing platforms and services able to exploit the full potential of 5G networks.”

“Today, Reply combines great financial solidity with a variety of skills that are unique on the market, combined with an execution and delivery capacity of the highest quality” Mario Rizzante concludes. “This mix enables us to face the coming months with determination, with the aim of establishing ourselves in those innovation niches that will increasingly be decisive in the daily lives of people and companies, such as green tech and all the as yet largely unexplored areas created by the fusion of the digital world with the physical world through the combined use of technologies such as digital twin, artificial intelligence, robotics and augmented reality."

The manager responsible for preparing the company's financial reports, Dr Giuseppe Veneziano, states in accordance with Paragraph 2 of Article 154-bis of the Consolidated Finance Act, that the accounting information contained in this press release corresponds to the company's records, ledgers and accounting entries.

REPLY
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. Reply is a network of highly specialised companies supporting key European industrial groups operating in the telecom and media, industry and services, banking, insurance and public administration sectors in the definition and development of business models enabled for the new paradigms of AI, cloud computing, digital media and the Internet of Things. Reply services include: Consulting, System Integration and Digital Services. www.reply.com

This press release is a translation, the Italian version will prevail.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts

Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594

Investor Relation Contacts

Reply
Riccardo Lodigiani
r.lodigiani@reply.com
Tel. +390117711594

Michael Lueckenkoetter
m.lueckenkoetter@reply.com
Tel. +49524150091017

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 09:00:00 EEST | Press release

Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Through Reporting (STR) vision and leveraging the combined capabilities of the transaction to deliver more resilient, transparen

AB InBev Reports First Quarter 2026 Results5.5.2026 08:02:00 EEST | Press release

Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504526109/en/ Regulated information1 “Cheers to beer - the strength of the category and the consistent execution of our consumer-centric strategy drove continued momentum across our footprint. We are investing behind our megabrands and innovations to lead and grow the category. With strong execution by our teams and major moments of celebration ahead, we are well positioned for 2026.” – Michel Doukeris, CEO, AB InBev Revenue +5.8% Revenue increased by 5.8% with revenue per hl growth of 4.5%. Reported revenue increased by 12.0% to 15 267 million USD, positively impacted by currency translation. 8.2% increase in combined revenues of megabrands, led by Corona, which grew by 16% outside of its home market. 27% increase in revenue of no-alcohol beer. 37% increase in revenue of Beyond Beer. 55% increase in Gross Mer

Kerecis Drives the Fish-Skin Conversation at Leading European Wound Conference - EWMA-DEWU 20264.5.2026 21:25:00 EEST | Press release

Kerecis, the company pioneering the use of sustainably sourced intact fish skin in cellular therapy and tissue regeneration, will play a prominent scientific and educational role at the EWMA‑DEWU 2026 Conference, taking place May 6–8 at the Messe & Congress Centrum Bremen in Bremen, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504487743/en/ MariCell® Solid This year, The European Wound Management Association's (EWMA) meeting is held in conjunction with the Deutscher Wundkongress (DEWU); combining two major wound-care congresses into a single forum for scientific exchange, education, and clinical discussion. At this year’s conference, Kerecis will highlight growing clinical experience with intact fish‑skin grafts across a broad range of wound indications, supported by two Kerecis‑led scientific symposia, multiple oral and poster presentations, and direct engagement with clinicians at Booth D30, located adjacent

Printing the Future of Medicine: CTIBIOTECH™ Announces $27 Million Investment to Launch U.S. Operations at the SelectUSA Investment Summit4.5.2026 21:00:00 EEST | Press release

CTIBIOTECH™, a pioneering Contract Research, Development, and Manufacturing Organization (CRDMO) and global leader in 3D bioprinting of human tissues, today officially announces the launch of its North American subsidiary, CTIBIOTECH USA™. The official launch took place today at the prestigious SelectUSA Investment Summit in Washington, D.C. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504107996/en/ From Biopsy to Breakthrough, CTIBIOTECH USA™'s Vision for Precision Medicine Operating from its new United States base in the thriving life sciences “Cellicon Valley” hub of Philadelphia, Pennsylvania, in association with BioLabs for Advanced Therapeutics, CTIBIOTECH USA™ will provide the company's proprietary human cell and tissue bioassays and New Approach Methods (NAMs) directly to North American pharmaceutical, biomedical, and dermatocosmetics markets. By producing and supplying these cutting-edge human bioassays domesti

Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 18:16:00 EEST | Press release

Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye